Professor of Surgery Brigham and Women's Hospital, Dana Farber Cancer Institute Boston, Massachusetts, United States
The role of neoadjuvant therapy for patients with both invasive cancer and pre-malignant breast disease is rapidly evolving. The purpose of this session is to review current data and ongoing trials to provide guidance on breast cancer treatment, including specific immunotherapies and surgical timing.
